Review of Pharmacological Options for the Treatment of Chagas Disease

Lascano, Fernanda; BOURNISSEN, FACUNDO GARCIA; Altcheh, Jaime

doi:10.22541/au.160133501.13498728

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, this should be considered by healthcare teams to eliminate the belief that people with Chagas disease are only those migrating from rural or historically endemic areas. Additionally, this reinforces the need to accomplish the guidelines of universal active screening for Chagas disease in pregnant women and their infants as well as to implement the treatment of women of a fertile age to prevent CCD transmission [ 3 , 28 , 29 ].…”

Section: Discussionmentioning

confidence: 89%

Diagnostic Accuracy of Two Molecular Tools for Diagnosis of Congenital Chagas Disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background and Objective The real prevalence of congenital Chagas disease is undefined because of difficulties in the detection of Trypanosoma cruzi by microscopic examination. The aim of this study was to determine the diagnostic accuracy of two molecular diagnostic tools, qPCR and LAMP, in the diagnosis of congenital Chagas disease in a clinical setting. Methods To this end, we conducted a prospective cohort study in a tertiary care center, of infants under 9 months of age, born in Buenos Aires to women with Chagas disease. Blood samples were collected for microscopic examination and molecular diagnosis at baseline. If negative, infants were followed up until 9 months of age to determine a final diagnosis by serology. In-house qPCR and LAMP previously validated were challenged as index tests. Results A total of 154 participants were potentially eligible, 120 of whom were enrolled. Finally, 102 (66.2%) of them fulfilled the follow-up. The diagnosis of congenital Chagas disease was confirmed in 13 infants and excluded in 89. Both the sensitivity and specificity of the qPCR were 100.0% (95% confidence interval 75.3–100.0 and 95% confidence interval 95.9–100.0, respectively), whereas the sensitivity and specificity of LAMP were 69.2% (95% confidence interval 38.6–90.9) and 100% (95% confidence interval 95.9–100.0), respectively. Conclusions The qPCR agreed with the current diagnostic algorithm, and was a reliable and sensitive tool to detect congenital Chagas disease earlier, providing an appropriate and timely identification of infected infants requiring treatment. LAMP was able to detect congenital Chagas disease in infected infants by naked-eye visualization in accordance with a microscopic examination. The advantages of molecular diagnostic tools should be taken into account by the health system to improve congenital Chagas disease diagnosis.

show abstract

Section: Discussionmentioning

confidence: 89%

Diagnostic Accuracy of Two Molecular Tools for Diagnosis of Congenital Chagas Disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020

Kaykı-Mutlu

Michel

2021

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

While the COVID-19 pandemic also affected the work of regulatory authorities, the US Food and Drug Administration approved a total of 53 new drugs in 2020, one of the highest numbers in the past decades. Most newly approved drugs related to oncology (34%) and neurology (15%). We discuss these new drugs by level of innovation they provide, i.e., first to treat a condition, first using a novel mechanisms of action, and “others.” Six drugs were first in indication, 15 first using a novel mechanism of action, and 32 other. This includes many drugs for the treatment of orphan indications and some for the treatment of tropical diseases previously neglected for commercial reasons. Small molecules continue to dominate new drug approvals, followed by antibodies. Of note, newly approved drugs also included small-interfering RNAs and antisense oligonucleotides. These data show that the trend for declines in drug discovery and development has clearly been broken.

show abstract

Recent Progress in the Development of Indole-Based Compounds Active against Malaria, Trypanosomiasis and Leishmaniasis

Pacheco

Santos

2022

Molecules

View full text Add to dashboard Cite

Human protozoan diseases represent a serious health problem worldwide, affecting mainly people in social and economic vulnerability. These diseases have attracted little investment in drug discovery, which is reflected in the limited available therapeutic arsenal. Authorized drugs present problems such as low efficacy in some stages of the disease or toxicity, which result in undesirable side effects and treatment abandonment. Moreover, the emergence of drug-resistant parasite strains makes necessary an even greater effort to develop safe and effective antiparasitic agents. Among the chemotypes investigated for parasitic diseases, the indole nucleus has emerged as a privileged molecular scaffold for the generation of new drug candidates. In this review, the authors provide an overview of the indole-based compounds developed against important parasitic diseases, namely malaria, trypanosomiasis and leishmaniasis, by focusing on the design, optimization and synthesis of the most relevant synthetic indole scaffolds recently reported.

show abstract

Review of Pharmacological Options for the Treatment of Chagas Disease

Cited by 3 publications

References 0 publications

Diagnostic Accuracy of Two Molecular Tools for Diagnosis of Congenital Chagas Disease

Diagnostic Accuracy of Two Molecular Tools for Diagnosis of Congenital Chagas Disease

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020

Recent Progress in the Development of Indole-Based Compounds Active against Malaria, Trypanosomiasis and Leishmaniasis

Contact Info

Product

Resources

About